临床终点
头颈部癌
医学
头颈部
临床试验
肿瘤科
基底细胞
代理终结点
癌症
头颈部鳞状细胞癌
内科学
外科
作者
Annette M. Lim,Akihiro Homma,Amanda Psyrri,Christophe Le Tourneau,Amanda Psyrri,Amanda Psyrri,David Thomson,Amanda Psyrri,Christina Henson,Akihiro Homma,Amanda Psyrri,James E. Bates,Smaro Lazarakis,Juliette Thariat,Amanda Psyrri,Hisham Mehanna,Conor E. Steuer
标识
DOI:10.1016/s1470-2045(24)00067-6
摘要
Robust time-to-event endpoint definitions are crucial for the assessment of treatment effect and the clinical value of trial interventions. Here, the Head and Neck Cancer International Group investigated endpoint use in phase 3 trials and trials considered potentially practice-changing published between 2008 and 2021 in the curative-intent setting for patients with mucosal head and neck squamous cell carcinoma. Of the 92 trials reviewed, we show that all core components of endpoint reporting were heterogeneous, including definitions of common terms, such as overall survival and progression-free survival. Our report highlights the urgent need for harmonisation of fundamental components of clinical trial endpoints and the engagement of all stakeholders to ensure the transparent reporting of endpoint details.
科研通智能强力驱动
Strongly Powered by AbleSci AI